Purpose

This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high risk prostate cancer and low gene risk score. This trial also compares more intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in patients with high risk prostate cancer and high gene risk score. Apalutamide may help fight prostate cancer by blocking the use of androgen by the tumor cells. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Giving a shorter hormone therapy treatment may work the same at controlling prostate cancer compared to the usual 24 month hormone therapy treatment in patients with low gene risk score. Adding apalutamide to the usual treatment may increase the length of time without prostate cancer spreading as compared to the usual treatment in patients with high gene risk score.

Conditions

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
Male
Accepts Healthy Volunteers
No

Inclusion Criteria

  • PRIOR TO STEP 1 REGISTRATION - Pathologically proven diagnosis of adenocarcinoma of prostate cancer within 180 days prior to registration - High-risk disease defined as having at least one or more of the following: - PSA > 20 ng/mL prior to starting ADT Note: Patients receiving a 5-alpha reductase inhibitor (ex. finasteride) at the time of enrollment are eligible. The baseline PSA value should be doubled for PSAs taken while on 5-alpha reductase inhibitors and the medication should be discontinued prior to randomization but a washout period is not required. - cT3a-T4 by digital exam or imaging (American Joint Committee on Cancer [AJCC] 8th edition [Ed.]) - Gleason score of 8-10 - Node positive by conventional imaging with a short axis of at least 1.0 cm - Appropriate stage for study entry based on the following diagnostic workup: - History/physical examination within 120 days prior to registration; - Bone imaging within 120 days prior to registration; - Note: To be eligible, patient must have no definitive evidence of bone metastases (M0) on bone scan or sodium fluoride (NaF) PET within 120 days prior to registration (negative NaF PET/CT or negative Axumin or choline PET or negative fluciclovine, choline or prostate-specific membrane antigen (PSMA) PET within 120 days prior to registration is an acceptable substitute if they have been performed). Patients who have bone metastases established only fluciclovine, choline, or PSMA PET but not definitive on bone scan or NaF PET will still be eligible - CT or MRI of the pelvis within 120 days prior to registration (negative fluciclovine, choline, or PSMA PET within 120 days prior to registration is an acceptable substitute). As with bone staging, nodal staging for trial purposes will be based off of conventional imaging findings only - Patients with confirmed N1 metastases on conventional imaging (CT/MRI) as defined by ≥10 mm on short axis are eligible but will be automatically assigned to the intensification study. Patients who are positive by fluciclovine, choline, or PSMA PET (i.e. N1), but whose nodes do not meet traditional size criteria for positivity (i.e. they measure ≥ 10 mm on either the CT or MRI portion of the PET or on a dedicated CT or MRI) will not be considered N1 for the trial and will not automatically be assigned to the intensification study - Age ≥ 18 - Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 within 120 days prior to registration - Hemoglobin ≥ 9.0 g/dL, independent of transfusion and/or growth factors (within 120 days prior to registration) - Platelet count ≥ -100 x 10^3/uL independent of transfusion and/or growth factors (within 120 days prior to registration) - Creatinine clearance (CrCl) ≥ 30 mL/min estimated by Cockcroft-Gault equation (within 120 days prior to registration) - For Black patients whose renal function is not considered adequate by Cockcroft-Gault formula, an alternative formula that takes race into account (Chronic Kidney Disease Epidemiology Collaboration CKD-EPI formula) may be used for calculating creatinine clearance for trial eligibility - Either a CrCl ≥ 30 ml/min or calculated glomerular filtration rate (GFR) ≥ 30 will make a patient eligible - Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (within 120 days prior to registration) - Note: In subjects with Gilbert's syndrome, if total bilirubin is > 1.5 x ULN, measure direct and indirect bilirubin and if direct bilirubin is ≤ 1.5 x ULN, subject is eligible - Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) or alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) ≤ 2.5 x institutional ULN (within 120 days prior to registration) - Serum albumin ≥ 3.0 g/dL (within 120 days prior to registration) - The patient must agree to use a condom (even men with vasectomies) and another effective method of birth control if he is having sex with a woman of childbearing potential or agree to use a condom if he is having sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drug - Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial and have a CD4 count ≥ 200 cells/microliter within 60 days prior to registration. Note: HIV testing is not required for eligibility for this protocol. Of note, for patients with HIV in the intensification trial randomized to apalutamide, highly active antiretroviral therapy (HAART) may need to be adjusted to medications that do not interact with apalutamide - For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable after or on suppressive therapy within 60 days prior to registration, if indicated. Note: HBV viral testing is not required for eligibility for this protocol - Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. Note: Any patient with a cancer (other than keratinocyte carcinoma or carcinoma in situ or low-grade non-muscle invasive bladder cancer) who has been disease-free for less than 3 years must contact the principal investigator - The patient or a legally authorized representative must provide study-specific informed consent prior to study entry - PRIOR TO STEP 2 RANDOMIZATION - Confirmation of Decipher score - Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load within 60 days prior. Note: Apalutamide may interfere with HCV drugs. Patients on HCV medications should alert their infectious diseases physician if they get randomized to apalutamide due to the possibility that apalutamide can affect the bioavailability of some HCV medications. HCV viral testing is not required for eligibility for this protocol - For patients entering the Intensification Cohort ONLY: Patients must discontinue or substitute concomitant medications known to lower the seizure threshold at least 30 days prior to Step 2 randomization

Exclusion Criteria

  • PRIOR TO STEP 1 REGISTRATION: - Definitive radiologic evidence of metastatic disease outside of the pelvic nodes (M1a, M1b or M1c) on conventional imaging (i.e. bone scan, CT scan, MRI) - Prior systemic chemotherapy within ≤ 3 years prior to registration; note that prior chemotherapy for a different cancer is allowed (completed > 3 years prior to registration - Prior radical prostatectomy - Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields - Current use of 5-alpha reductase inhibitor. NOTE: If the alpha reductase inhibitor is stopped prior to randomization the patient is eligible - History of any of the following: - Seizure disorder - Current severe or unstable angina - New York Heart Association Functional Classification III/IV (Note: Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification.) - History of any condition that in the opinion of the investigator, would preclude participation in this study - Evidence of any of the following at registration: - Active uncontrolled infection requiring IV antibiotics - Baseline severe hepatic impairment (Child Pugh Class C) - Inability to swallow oral pills - Any current condition that in the opinion of the investigator, would preclude participation in this study - Prior pharmacologic androgen ablation for prostate cancer is allowed only if the onset of androgen ablation (both luteinizing hormone-releasing hormone [LHRH] agonist and oral anti-androgen) is ≤ 60 days prior to registration; Please note: baseline PSA must be obtained prior to the start of any ADT - PRIOR TO STEP 2 RANDOMIZATION: - Evidence of known gastrointestinal disorder affecting absorption of oral medications at registration - For patients entering the Intensification Cohort ONLY: Presence of uncontrolled hypertension (persistent systolic blood pressure [BP] ≥ 160 mmHg or diastolic BP ≥ 100 mmHg). Subjects with a history of hypertension are allowed, provided that BP is controlled to within these limits by anti-hypertensive treatment

Study Design

Phase
Phase 3
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Active Comparator
Arm I (de-intensification study)
Patients undergo RT over 2-11 weeks and receive ADT (consisting of either leuprolide, goserelin, triptorelin, degarelix, buserelin or histrelin and bicalutamide or flutamide) for 24 months in the absence of disease progression or unacceptable toxicity.
  • Drug: Bicalutamide
    Antiandrogen
    Other names:
    • Casodex
    • Cosudex
    • ICI 176,334
    • ICI 176334
  • Drug: Buserelin
    Luteinizing hormone-releasing hormone (LHRH) agonist
    Other names:
    • 6-[O-(1,1-Dimethylethyl)-D-serine]-9-(N-ethyl-L-prolinamide)-10-deglycinamide-luteinizing Hormone-releasing Factor (Pig)
    • BSRL
    • Busereline
    • Etilamide
    • HOE 766
    • ICI 123215
    • S74-6766
  • Drug: Degarelix
    Gonadotropin-releasing hormone (GnRH) antagonist
    Other names:
    • FE200486
    • Firmagon
  • Drug: Flutamide
    Antiandrogen
    Other names:
    • 4'-Nitro-3'-trifluoromethylisobutyranilide
    • Apimid
    • Cebatrol
    • Chimax
    • Cytomid
    • Drogenil
    • Euflex
    • Eulexine
    • Flucinom
    • Flucinome
    • Flugerel
    • Fluken
    • Flulem
    • FLUT
    • Fluta-Gry
    • Flutabene
    • Flutacan
    • Flutamex
    • Flutamin
    • Flutan
    • Flutaplex
    • Fugerel
    • Grisetin
    • Niftolide
    • Oncosal
    • Profamid
    • Propanamide, 2-Methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-
    • Prostacur
    • Prostadirex
    • Prostica
    • Prostogenat
    • Sch 13521
    • Tafenil
    • Tecnoflut
    • Testotard
  • Drug: Goserelin
    Gonadotropin-releasing hormone (GnRH) agonist
    Other names:
    • ICI-118630
  • Drug: Histrelin
    Gonadotropin-releasing hormone (GnRH) agonist
  • Drug: Leuprolide
    Gonadotropin-releasing hormone (GnRH) agonist
    Other names:
    • Leuprorelin
  • Other: Quality-of-Life Assessment
    Ancillary studies
    Other names:
    • Quality of Life Assessment
  • Other: Questionnaire Administration
    Ancillary studies
  • Radiation: Radiation Therapy
    Undergo radiation therapy
    Other names:
    • Cancer Radiotherapy
    • ENERGY_TYPE
    • Irradiate
    • Irradiated
    • Irradiation
    • Radiation
    • Radiation Therapy, NOS
    • Radiotherapeutics
    • Radiotherapy
    • RT
    • Therapy, Radiation
  • Drug: Triptorelin
    Gonadotropin-releasing hormone (GnRH) agonist
    Other names:
    • 6-D-Tryptophan-LH-RH
    • 6-D-Tryptophanluteinizing Hormone-releasing Factor
    • AY-25650
    • CL-118,532
    • Detryptoreline
Experimental
Arm II (de-intensification study)
Patients undergo RT over 2-11 weeks and receive ADT (consisting of either leuprolide, goserelin, triptorelin, degarelix, buserelin or histrelin and bicalutamide or flutamide) for 12 months in the absence of disease progression or unacceptable toxicity.
  • Drug: Bicalutamide
    Antiandrogen
    Other names:
    • Casodex
    • Cosudex
    • ICI 176,334
    • ICI 176334
  • Drug: Buserelin
    Luteinizing hormone-releasing hormone (LHRH) agonist
    Other names:
    • 6-[O-(1,1-Dimethylethyl)-D-serine]-9-(N-ethyl-L-prolinamide)-10-deglycinamide-luteinizing Hormone-releasing Factor (Pig)
    • BSRL
    • Busereline
    • Etilamide
    • HOE 766
    • ICI 123215
    • S74-6766
  • Drug: Degarelix
    Gonadotropin-releasing hormone (GnRH) antagonist
    Other names:
    • FE200486
    • Firmagon
  • Drug: Flutamide
    Antiandrogen
    Other names:
    • 4'-Nitro-3'-trifluoromethylisobutyranilide
    • Apimid
    • Cebatrol
    • Chimax
    • Cytomid
    • Drogenil
    • Euflex
    • Eulexine
    • Flucinom
    • Flucinome
    • Flugerel
    • Fluken
    • Flulem
    • FLUT
    • Fluta-Gry
    • Flutabene
    • Flutacan
    • Flutamex
    • Flutamin
    • Flutan
    • Flutaplex
    • Fugerel
    • Grisetin
    • Niftolide
    • Oncosal
    • Profamid
    • Propanamide, 2-Methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-
    • Prostacur
    • Prostadirex
    • Prostica
    • Prostogenat
    • Sch 13521
    • Tafenil
    • Tecnoflut
    • Testotard
  • Drug: Goserelin
    Gonadotropin-releasing hormone (GnRH) agonist
    Other names:
    • ICI-118630
  • Drug: Histrelin
    Gonadotropin-releasing hormone (GnRH) agonist
  • Drug: Leuprolide
    Gonadotropin-releasing hormone (GnRH) agonist
    Other names:
    • Leuprorelin
  • Other: Quality-of-Life Assessment
    Ancillary studies
    Other names:
    • Quality of Life Assessment
  • Other: Questionnaire Administration
    Ancillary studies
  • Radiation: Radiation Therapy
    Undergo radiation therapy
    Other names:
    • Cancer Radiotherapy
    • ENERGY_TYPE
    • Irradiate
    • Irradiated
    • Irradiation
    • Radiation
    • Radiation Therapy, NOS
    • Radiotherapeutics
    • Radiotherapy
    • RT
    • Therapy, Radiation
  • Drug: Triptorelin
    Gonadotropin-releasing hormone (GnRH) agonist
    Other names:
    • 6-D-Tryptophan-LH-RH
    • 6-D-Tryptophanluteinizing Hormone-releasing Factor
    • AY-25650
    • CL-118,532
    • Detryptoreline
Active Comparator
Arm III (intensification study)
Patients undergo RT over 2-11 weeks and receive ADT as in Arm I.
  • Drug: Bicalutamide
    Antiandrogen
    Other names:
    • Casodex
    • Cosudex
    • ICI 176,334
    • ICI 176334
  • Drug: Buserelin
    Luteinizing hormone-releasing hormone (LHRH) agonist
    Other names:
    • 6-[O-(1,1-Dimethylethyl)-D-serine]-9-(N-ethyl-L-prolinamide)-10-deglycinamide-luteinizing Hormone-releasing Factor (Pig)
    • BSRL
    • Busereline
    • Etilamide
    • HOE 766
    • ICI 123215
    • S74-6766
  • Drug: Degarelix
    Gonadotropin-releasing hormone (GnRH) antagonist
    Other names:
    • FE200486
    • Firmagon
  • Drug: Flutamide
    Antiandrogen
    Other names:
    • 4'-Nitro-3'-trifluoromethylisobutyranilide
    • Apimid
    • Cebatrol
    • Chimax
    • Cytomid
    • Drogenil
    • Euflex
    • Eulexine
    • Flucinom
    • Flucinome
    • Flugerel
    • Fluken
    • Flulem
    • FLUT
    • Fluta-Gry
    • Flutabene
    • Flutacan
    • Flutamex
    • Flutamin
    • Flutan
    • Flutaplex
    • Fugerel
    • Grisetin
    • Niftolide
    • Oncosal
    • Profamid
    • Propanamide, 2-Methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-
    • Prostacur
    • Prostadirex
    • Prostica
    • Prostogenat
    • Sch 13521
    • Tafenil
    • Tecnoflut
    • Testotard
  • Drug: Goserelin
    Gonadotropin-releasing hormone (GnRH) agonist
    Other names:
    • ICI-118630
  • Drug: Histrelin
    Gonadotropin-releasing hormone (GnRH) agonist
  • Drug: Leuprolide
    Gonadotropin-releasing hormone (GnRH) agonist
    Other names:
    • Leuprorelin
  • Other: Quality-of-Life Assessment
    Ancillary studies
    Other names:
    • Quality of Life Assessment
  • Other: Questionnaire Administration
    Ancillary studies
  • Radiation: Radiation Therapy
    Undergo radiation therapy
    Other names:
    • Cancer Radiotherapy
    • ENERGY_TYPE
    • Irradiate
    • Irradiated
    • Irradiation
    • Radiation
    • Radiation Therapy, NOS
    • Radiotherapeutics
    • Radiotherapy
    • RT
    • Therapy, Radiation
  • Drug: Triptorelin
    Gonadotropin-releasing hormone (GnRH) agonist
    Other names:
    • 6-D-Tryptophan-LH-RH
    • 6-D-Tryptophanluteinizing Hormone-releasing Factor
    • AY-25650
    • CL-118,532
    • Detryptoreline
Experimental
Arm IV (intensification study)
Patients undergo RT over 2-11 weeks and receive ADT (consisting of either leuprolide, goserelin, triptorelin, degarelix, buserelin or histrelin) for 24 months in the absence of disease progression or unacceptable toxicity. Patients also receive apalutamide PO QD. Treatment repeats every 90 days for up to 8 cycles (24 months) in the absence of disease progression or unacceptable toxicity.
  • Drug: Apalutamide
    Nonsteroidal Antiandrogen
    Other names:
    • ARN 509
    • ARN-509
    • ARN509
    • Erleada
    • JNJ 56021927
    • JNJ-56021927
  • Drug: Buserelin
    Luteinizing hormone-releasing hormone (LHRH) agonist
    Other names:
    • 6-[O-(1,1-Dimethylethyl)-D-serine]-9-(N-ethyl-L-prolinamide)-10-deglycinamide-luteinizing Hormone-releasing Factor (Pig)
    • BSRL
    • Busereline
    • Etilamide
    • HOE 766
    • ICI 123215
    • S74-6766
  • Drug: Degarelix
    Gonadotropin-releasing hormone (GnRH) antagonist
    Other names:
    • FE200486
    • Firmagon
  • Drug: Goserelin
    Gonadotropin-releasing hormone (GnRH) agonist
    Other names:
    • ICI-118630
  • Drug: Histrelin
    Gonadotropin-releasing hormone (GnRH) agonist
  • Drug: Leuprolide
    Gonadotropin-releasing hormone (GnRH) agonist
    Other names:
    • Leuprorelin
  • Other: Quality-of-Life Assessment
    Ancillary studies
    Other names:
    • Quality of Life Assessment
  • Other: Questionnaire Administration
    Ancillary studies
  • Radiation: Radiation Therapy
    Undergo radiation therapy
    Other names:
    • Cancer Radiotherapy
    • ENERGY_TYPE
    • Irradiate
    • Irradiated
    • Irradiation
    • Radiation
    • Radiation Therapy, NOS
    • Radiotherapeutics
    • Radiotherapy
    • RT
    • Therapy, Radiation
  • Drug: Triptorelin
    Gonadotropin-releasing hormone (GnRH) agonist
    Other names:
    • 6-D-Tryptophan-LH-RH
    • 6-D-Tryptophanluteinizing Hormone-releasing Factor
    • AY-25650
    • CL-118,532
    • Detryptoreline

Recruiting Locations

Fairbanks Memorial Hospital
Fairbanks, Alaska 99701
Contact:
Site Public Contact
907-458-3043
Veronica.Stevenson@foundationhealth.org

Arizona Breast Cancer Specialists-Gilbert
Gilbert, Arizona 85297
Contact:
Site Public Contact
480-922-4600

Arizona Center for Cancer Care-Peoria
Peoria, Arizona 85381
Contact:
Site Public Contact
623-773-2873

Arizona Breast Cancer Specialists-Scottsdale
Scottsdale, Arizona 85258
Contact:
Site Public Contact
480-922-4600

University of Arizona Cancer Center-North Campus
Tucson, Arizona 85719
Contact:
Site Public Contact
UACC-IIT@uacc.arizona.edu

University of Arkansas for Medical Sciences
Little Rock, Arkansas 72205
Contact:
Site Public Contact
501-686-8274

Sutter Cancer Centers Radiation Oncology Services-Auburn
Auburn, California 95603
Contact:
Site Public Contact
NCIclinicaltrials@sutterhealth.org

AIS Cancer Center at San Joaquin Community Hospital
Bakersfield, California 93301
Contact:
Site Public Contact
661-323-4673

City of Hope Comprehensive Cancer Center
Duarte, California 91010
Contact:
Site Public Contact
800-826-4673
becomingapatient@coh.org

Kaiser Permanente Dublin
Dublin, California 94568
Contact:
Site Public Contact
877-642-4691

Kaiser Permanente-Fremont
Fremont, California 94538
Contact:
Site Public Contact
877-642-4691
Kpoct@kp.org

Washington Hospital
Fremont, California 94538
Contact:
Site Public Contact
510-745-6433

Kaiser Permanente-Fresno
Fresno, California 93720
Contact:
Site Public Contact
877-642-4691
Kpoct@kp.org

Marin General Hospital
Greenbrae, California 94904
Contact:
Site Public Contact
415-925-7325

City of Hope at Irvine Lennar
Irvine, California 92618
Contact:
Site Public Contact
877-467-3411

UC San Diego Moores Cancer Center
La Jolla, California 92093
Contact:
Site Public Contact
858-822-5354
cancercto@ucsd.edu

City of Hope Antelope Valley
Lancaster, California 93534
Contact:
Site Public Contact
800-826-4673
becomingapatient@coh.org

Cedars Sinai Medical Center
Los Angeles, California 90048
Contact:
Site Public Contact
310-423-8965

Fremont - Rideout Cancer Center
Marysville, California 95901
Contact:
Site Public Contact
530-749-4400

Memorial Medical Center
Modesto, California 95355
Contact:
Site Public Contact
NCIclinicaltrials@sutterhealth.org

Kaiser Permanente-Modesto
Modesto, California 95356
Contact:
Site Public Contact
877-642-4691
Kpoct@kp.org

Providence Queen of The Valley
Napa, California 94558
Contact:
Site Public Contact
707-521-3830

Kaiser Permanente-Oakland
Oakland, California 94611
Contact:
Site Public Contact
877-642-4691
Kpoct@kp.org

Saint Joseph Hospital - Orange
Orange, California 92868
Contact:
Site Public Contact
714-734-6220

UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California 92868
Contact:
Site Public Contact
877-827-8839
ucstudy@uci.edu

Stanford Cancer Institute Palo Alto
Palo Alto, California 94304
Contact:
Site Public Contact
650-498-7061
ccto-office@stanford.edu

Kaiser Permanente-Roseville
Roseville, California 95661
Contact:
Site Public Contact
877-642-4691
Kpoct@kp.org

Sutter Cancer Centers Radiation Oncology Services-Roseville
Roseville, California 95661
Contact:
Site Public Contact
NCIclinicaltrials@sutterhealth.org

Kaiser Permanente Downtown Commons
Sacramento, California 95814
Contact:
Site Public Contact
877-642-4691
kpoct@kp.org

Sutter Medical Center Sacramento
Sacramento, California 95816
Contact:
Site Public Contact
NCIclinicaltrials@sutterhealth.org

University of California Davis Comprehensive Cancer Center
Sacramento, California 95817
Contact:
Site Public Contact
916-734-3089

Kaiser Permanente-South Sacramento
Sacramento, California 95823
Contact:
Site Public Contact
877-642-4691
Kpoct@kp.org

Kaiser Permanente-San Francisco
San Francisco, California 94115
Contact:
Site Public Contact
877-642-4691
Kpoct@kp.org

UCSF Medical Center-Mission Bay
San Francisco, California 94158
Contact:
Site Public Contact
877-827-3222
cancertrials@ucsf.edu

Kaiser Permanente-Santa Teresa-San Jose
San Jose, California 95119
Contact:
Site Public Contact
877-642-4691
Kpoct@kp.org

Stanford Cancer Center South Bay
San Jose, California 95124
Contact:
Site Public Contact
650-498-7061
ccto-office@stanford.edu

Kaiser Permanente San Leandro
San Leandro, California 94577
Contact:
Site Public Contact
877-642-4691
Kpoct@kp.org

UCSF Cancer Center - San Mateo
San Mateo, California 94402
Contact:
Site Public Contact
877-827-3222
cancertrials@ucsf.edu

Ridley-Tree Cancer Center
Santa Barbara, California 93105
Contact:
Site Public Contact
research@ridleytreecc.org

Kaiser Permanente Medical Center - Santa Clara
Santa Clara, California 95051
Contact:
Site Public Contact
877-642-4691
Kpoct@kp.org

Kaiser Permanente-Santa Rosa
Santa Rosa, California 95403
Contact:
Site Public Contact
877-642-4691
Kpoct@kp.org

City of Hope South Pasadena
South Pasadena, California 91030
Contact:
Site Public Contact
800-826-4673
becomingapatient@coh.org

Kaiser Permanente-South San Francisco
South San Francisco, California 94080
Contact:
Site Public Contact
877-642-4691
Kpoct@kp.org

Cedars-Sinai Cancer - Tarzana
Tarzana, California 91356
Contact:
Site Public Contact
818-981-3818

Torrance Memorial Physician Network - Cancer Care
Torrance, California 90505
Contact:
Site Public Contact
310-750-3300
courtney.steeneken@tmphysicians.com

Torrance Memorial Medical Center
Torrance, California 90509
Contact:
Site Public Contact
310-517-4665

Gene Upshaw Memorial Tahoe Forest Cancer Center
Truckee, California 96161
Contact:
Site Public Contact
530-582-6450

City of Hope Upland
Upland, California 91786
Contact:
Site Public Contact
800-826-4673
becomingapatient@coh.org

Kaiser Permanente-Vallejo
Vallejo, California 94589
Contact:
Site Public Contact
877-642-4691
Kpoct@kp.org

Kaiser Permanente-Walnut Creek
Walnut Creek, California 94596
Contact:
Site Public Contact
877-642-4691
Kpoct@kp.org

John Muir Medical Center-Walnut Creek
Walnut Creek, California 94598
Contact:
Site Public Contact
925-941-4246

UCHealth University of Colorado Hospital
Aurora, Colorado 80045
Contact:
Site Public Contact
720-848-0650

Rocky Mountain Cancer Centers-Boulder
Boulder, Colorado 80304
Contact:
Site Public Contact
303-777-2663
info@westernstatesncorp.org

UCHealth Memorial Hospital Central
Colorado Springs, Colorado 80909
Contact:
Site Public Contact
719-365-2406

Memorial Hospital North
Colorado Springs, Colorado 80920
Contact:
Site Public Contact
719-364-6700

Shaw Cancer Center
Edwards, Colorado 81632
Contact:
Site Public Contact
970-569-7429

Poudre Valley Hospital
Fort Collins, Colorado 80524
Contact:
Site Public Contact
970-297-6150

Cancer Care and Hematology-Fort Collins
Fort Collins, Colorado 80528
Contact:
Site Public Contact
412-339-5294
Roster@nrgoncology.org

North Colorado Medical Center
Greeley, Colorado 80631
Contact:
Site Public Contact
970-810-3046
BMDACCResearchCOMailbox@bannerhealth.com

UCHealth Greeley Hospital
Greeley, Colorado 80631
Contact:
Site Public Contact
412-339-5294
Roster@nrgoncology.org

UCHealth Highlands Ranch Hospital
Highlands Ranch, Colorado 80129
Contact:
Site Public Contact
720-848-0650

Medical Center of the Rockies
Loveland, Colorado 80538
Contact:
Site Public Contact
970-203-7083

McKee Medical Center
Loveland, Colorado 80539
Contact:
Site Public Contact
970-810-3046
BMDACCResearchCOMailbox@bannerhealth.com

Hartford HealthCare - Saint Vincent's Medical Center
Bridgeport, Connecticut 06606
Contact:
Site Public Contact
860-972-4700

Smilow Cancer Hospital-Derby Care Center
Derby, Connecticut 06418
Contact:
Site Public Contact
203-785-5702
canceranswers@yale.edu

Smilow Cancer Hospital Care Center-Fairfield
Fairfield, Connecticut 06824
Contact:
Site Public Contact
203-785-5702
canceranswers@yale.edu

Smilow Cancer Hospital Care Center at Greenwich
Greenwich, Connecticut 06830
Contact:
Site Public Contact
203-785-5702
canceranswers@yale.edu

Smilow Cancer Hospital Care Center - Guilford
Guilford, Connecticut 06437
Contact:
Site Public Contact
203-785-5702
canceranswers@yale.edu

Hartford Hospital
Hartford, Connecticut 06102
Contact:
Site Public Contact
860-545-5363

Smilow Cancer Hospital Care Center at Saint Francis
Hartford, Connecticut 06105
Contact:
Site Public Contact
203-785-5702
canceranswers@yale.edu

Midstate Medical Center
Meriden, Connecticut 06451
Contact:
Site Public Contact
866-662-5678

The Hospital of Central Connecticut
New Britain, Connecticut 06050
Contact:
Site Public Contact
860-224-5660

Yale University
New Haven, Connecticut 06520
Contact:
Site Public Contact
203-785-5702
canceranswers@yale.edu

Yale-New Haven Hospital North Haven Medical Center
North Haven, Connecticut 06473
Contact:
Site Public Contact
203-785-5702
canceranswers@yale.edu

Smilow Cancer Hospital-Orange Care Center
Orange, Connecticut 06477
Contact:
Site Public Contact
203-785-5702
canceranswers@yale.edu

Smilow Cancer Hospital Care Center at Long Ridge
Stamford, Connecticut 06902
Contact:
Site Public Contact
203-785-5702
canceranswers@yale.edu

Stamford Hospital/Bennett Cancer Center
Stamford, Connecticut 06904
Contact:
Site Public Contact
203-323-8944

Smilow Cancer Hospital Care Center-Trumbull
Trumbull, Connecticut 06611
Contact:
Site Public Contact
203-785-5702
canceranswers@yale.edu

Smilow Cancer Hospital Care Center - Waterford
Waterford, Connecticut 06385
Contact:
Site Public Contact
203-785-5702
canceranswers@yale.edu

Bayhealth Hospital Kent Campus
Dover, Delaware 19901
Contact:
Site Public Contact
302-744-6755
mary_ella_quillen@bayhealth.org

Helen F Graham Cancer Center
Newark, Delaware 19713
Contact:
Site Public Contact
302-623-4450
lbarone@christianacare.org

Medical Oncology Hematology Consultants PA
Newark, Delaware 19713
Contact:
Site Public Contact
302-623-4450
lbarone@christianacare.org

Boca Raton Regional Hospital
Boca Raton, Florida 33486
Contact:
Site Public Contact
561-955-4800

University of Florida Health Science Center - Gainesville
Gainesville, Florida 32610
Contact:
Site Public Contact
352-273-8010
cancer-center@ufl.edu

Miami Cancer Institute
Miami, Florida 33176
Contact:
Site Public Contact
786-596-2000

GenesisCare USA - Plantation
Plantation, Florida 33324
Contact:
Site Public Contact
941-833-5700
Rudi.Ross@usa.genesiscare.com

Tampa General Hospital
Tampa, Florida 33606
Contact:
Site Public Contact
813-844-7829
syapchanyk@tgh.org

Grady Health System
Atlanta, Georgia 30303
Contact:
Site Public Contact
404-489-9164

Emory Proton Therapy Center
Atlanta, Georgia 30308
Contact:
Site Public Contact
404-251-2854
allyson.anderson@emory.edu

Emory University Hospital Midtown
Atlanta, Georgia 30308
Contact:
Site Public Contact
888-946-7447

Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia 30322
Contact:
Site Public Contact
404-778-1868

Emory Saint Joseph's Hospital
Atlanta, Georgia 30342
Contact:
Site Public Contact
404-851-7115

Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
Savannah, Georgia 31405
Contact:
Site Public Contact
912-819-5704
underberga@sjchs.org

Rush - Copley Medical Center
Aurora, Illinois 60504
Contact:
Site Public Contact
630-978-6212
Cancer.Research@rushcopley.com

Advocate Good Shepherd Hospital
Barrington, Illinois 60010
Contact:
Site Public Contact
847-842-4847

Illinois CancerCare-Bloomington
Bloomington, Illinois 61704
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Illinois CancerCare-Canton
Canton, Illinois 61520
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Illinois CancerCare-Carthage
Carthage, Illinois 62321
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Northwestern University
Chicago, Illinois 60611
Contact:
Site Public Contact
312-695-1301
cancer@northwestern.edu

Rush University Medical Center
Chicago, Illinois 60612
Contact:
Site Public Contact
312-942-5498
clinical_trials@rush.edu

University of Illinois
Chicago, Illinois 60612
Contact:
Site Public Contact
312-355-3046

University of Chicago Comprehensive Cancer Center
Chicago, Illinois 60637
Contact:
Site Public Contact
773-702-8222
cancerclinicaltrials@bsd.uchicago.edu

Advocate Illinois Masonic Medical Center
Chicago, Illinois 60657
Contact:
Site Public Contact
773-296-5360

AMG Crystal Lake - Oncology
Crystal Lake, Illinois 60014
Contact:
Site Public Contact
630-929-6129
advocateresearch@advocate.com

Carle at The Riverfront
Danville, Illinois 61832
Contact:
Site Public Contact
800-446-5532
Research@Carle.com

Decatur Memorial Hospital
Decatur, Illinois 62526
Contact:
Site Public Contact
217-876-4762
morganthaler.jodi@mhsil.com

Northwestern Medicine Cancer Center Kishwaukee
DeKalb, Illinois 60115
Contact:
Site Public Contact
630-352-5360
Donald.Smith3@nm.org

Advocate Good Samaritan Hospital
Downers Grove, Illinois 60515
Contact:
Site Public Contact
630-275-1270
Barbara.barhamand@advocatehealth.com

Crossroads Cancer Center
Effingham, Illinois 62401
Contact:
Site Public Contact
217-876-4762
morganthaler.jodi@mhsil.com

Advocate Sherman Hospital
Elgin, Illinois 60123
Contact:
Site Public Contact
847-429-2907

Elmhurst Memorial Hospital
Elmhurst, Illinois 60126
Contact:
Site Public Contact
630-758-5460
Jrohde@emhc.org

Illinois CancerCare-Eureka
Eureka, Illinois 61530
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Illinois CancerCare-Galesburg
Galesburg, Illinois 61401
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Northwestern Medicine Cancer Center Delnor
Geneva, Illinois 60134
Contact:
Site Public Contact
630-352-5360
Donald.Smith3@nm.org

Advocate South Suburban Hospital
Hazel Crest, Illinois 60429
Contact:
Site Public Contact
708-799-9995

Illinois CancerCare-Kewanee Clinic
Kewanee, Illinois 61443
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Northwestern Medicine Lake Forest Hospital
Lake Forest, Illinois 60045
Contact:
Site Public Contact
cancertrials@northwestern.edu

AMG Libertyville - Oncology
Libertyville, Illinois 60048
Contact:
Site Public Contact
630-929-6129
advocateresearch@advocatehealth.com

Condell Memorial Hospital
Libertyville, Illinois 60048
Contact:
Site Public Contact
630-929-6129
advocateresearch@advocatehealth.com

Illinois CancerCare-Macomb
Macomb, Illinois 61455
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Carle Physician Group-Mattoon/Charleston
Mattoon, Illinois 61938
Contact:
Site Public Contact
800-446-5532
Research@carle.com

Loyola University Medical Center
Maywood, Illinois 60153
Contact:
Site Public Contact
708-226-4357

Edward Hospital/Cancer Center
Naperville, Illinois 60540
Contact:
Site Public Contact
630-646-6075

UC Comprehensive Cancer Center at Silver Cross
New Lenox, Illinois 60451
Contact:
Site Public Contact
773-702-8222
cancerclinicaltrials@bsd.uchicago.edu

Advocate Christ Medical Center
Oak Lawn, Illinois 60453-2699
Contact:
Site Public Contact
800-323-8622

University of Chicago Medicine-Orland Park
Orland Park, Illinois 60462
Contact:
Site Public Contact
773-702-8222
cancerclinicaltrials@bsd.uchicago.edu

Illinois CancerCare-Ottawa Clinic
Ottawa, Illinois 61350
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Advocate Lutheran General Hospital
Park Ridge, Illinois 60068
Contact:
Site Public Contact
847-384-3621

Illinois CancerCare-Pekin
Pekin, Illinois 61554
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Illinois CancerCare-Peoria
Peoria, Illinois 61615
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Methodist Medical Center of Illinois
Peoria, Illinois 61636
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

OSF Saint Francis Medical Center
Peoria, Illinois 61637
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Illinois CancerCare-Peru
Peru, Illinois 61354
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Illinois CancerCare-Princeton
Princeton, Illinois 61356
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

SwedishAmerican Regional Cancer Center/ACT
Rockford, Illinois 61114
Contact:
Site Public Contact
779-696-9378
lkline@uwhealth.org

Memorial Hospital East
Shiloh, Illinois 62269
Contact:
Site Public Contact
314-747-9912
dschwab@wustl.edu

Memorial Medical Center
Springfield, Illinois 62781
Contact:
Site Public Contact
217-528-7541
pallante.beth@mhsil.com

Carle Cancer Center
Urbana, Illinois 61801
Contact:
Site Public Contact
800-446-5532
Research@carle.com

Northwestern Medicine Cancer Center Warrenville
Warrenville, Illinois 60555
Contact:
Site Public Contact
630-352-5360
Donald.Smith3@nm.org

Illinois CancerCare - Washington
Washington, Illinois 61571
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Saint Luke's Hospital
Cedar Rapids, Iowa 52402
Contact:
Site Public Contact
319-368-5514
Rachel.varner@unitypoint.org

Mercy Hospital
Cedar Rapids, Iowa 52403
Contact:
Site Public Contact
319-365-4673

Oncology Associates at Mercy Medical Center
Cedar Rapids, Iowa 52403
Contact:
Site Public Contact
319-363-2690

Iowa Methodist Medical Center
Des Moines, Iowa 50309
Contact:
Site Public Contact
515-241-6727

Medical Oncology and Hematology Associates-Des Moines
Des Moines, Iowa 50309
Contact:
Site Public Contact
515-241-3305

Broadlawns Medical Center
Des Moines, Iowa 50314
Contact:
Site Public Contact
515-282-2200

University of Kansas Cancer Center
Kansas City, Kansas 66160
Contact:
Site Public Contact
913-588-3671
KUCC_Navigation@kumc.edu

Olathe Health Cancer Center
Olathe, Kansas 66061
Contact:
Site Public Contact
913-355-8000
Jeni.wakefield@olathehealth.org

University of Kansas Cancer Center-Overland Park
Overland Park, Kansas 66210
Contact:
Site Public Contact
913-588-3671
KUCC_Navigation@kumc.edu

Salina Regional Health Center
Salina, Kansas 67401
Contact:
Site Public Contact
785-452-7038
mleepers@srhc.com

University of Kansas Health System Saint Francis Campus
Topeka, Kansas 66606
Contact:
Site Public Contact
785-295-8000

University of Kansas Hospital-Westwood Cancer Center
Westwood, Kansas 66205
Contact:
Site Public Contact
913-588-3671
KUCC_Navigation@kumc.edu

Ascension Via Christi Hospitals Wichita
Wichita, Kansas 67214
Contact:
Site Public Contact
316-291-4774
research@viachristi.org

Saint Joseph Hospital East
Lexington, Kentucky 40509
Contact:
Site Public Contact
859-629-7169
ResearchInstituteInquiries@CommonSpirit.org

LSU Healthcare Network / Metairie Multi-Specialty Clinic
Metairie, Louisiana 70006
Contact:
Site Public Contact
504-210-3539
emede1@lsuhsc.edu

Tulane University School of Medicine
New Orleans, Louisiana 70112
Contact:
Site Public Contact
504-988-1147
bweimer1@tulane.edu

MaineHealth Coastal Cancer Treatment Center
Bath, Maine 04530
Contact:
Site Public Contact
412-339-5294
Roster@nrgoncology.org

Maine Medical Center-Bramhall Campus
Portland, Maine 04102
Contact:
Site Public Contact
207-885-7565

Penobscot Bay Medical Center
Rockport, Maine 04856
Contact:
Site Public Contact
207-396-8670
ClinicalResearch@mmc.org

MaineHealth Cancer Care Center of York County
Sanford, Maine 04073
Contact:
Site Public Contact
207-459-1600

Maine Medical Center- Scarborough Campus
Scarborough, Maine 04074
Contact:
Site Public Contact
207-396-8090
wrighd@mmc.org

Maine Medical Partners - South Portland
South Portland, Maine 04106
Contact:
Site Public Contact
207-396-8670
ClinicalResearch@mmc.org

Anne Arundel Medical Center
Annapolis, Maryland 21401
Contact:
Site Public Contact
443-481-1320
research@luminishealth.org

Maryland Proton Treatment Center
Baltimore, Maryland 21201
Contact:
Site Public Contact
410-369-5226
info@mdproton.com

University of Maryland/Greenebaum Cancer Center
Baltimore, Maryland 21201
Contact:
Site Public Contact
800-888-8823

Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland 21287
Contact:
Site Public Contact
410-955-8804
jhcccro@jhmi.edu

UM Upper Chesapeake Medical Center
Bel Air, Maryland 21014
Contact:
Site Public Contact
443-643-3010

Suburban Hospital
Bethesda, Maryland 20814
Contact:
Site Public Contact
301-896-2719
bsquill1@jhmi.edu

University of Maryland Shore Medical Center at Easton
Easton, Maryland 21601
Contact:
Site Public Contact
410-822-1000
Christina.weisenborn@umm.edu

Massachusetts General Hospital Cancer Center
Boston, Massachusetts 02114
Contact:
Site Public Contact
877-726-5130

Dana-Farber Cancer Institute
Boston, Massachusetts 02215
Contact:
Site Public Contact
877-442-3324

Dana-Farber/Brigham and Women's Cancer Center at Milford Regional
Milford, Massachusetts 01757
Contact:
Site Public Contact
877-332-4294

Dana-Farber/Brigham and Women's Cancer Center at South Shore
South Weymouth, Massachusetts 02190
Contact:
Site Public Contact
781-624-5000

Saint Joseph Mercy Hospital
Ann Arbor, Michigan 48106
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan 48109
Contact:
Site Public Contact
800-865-1125

McLaren Cancer Institute-Bay City
Bay City, Michigan 48706
Contact:
Site Public Contact
313-576-9790
ctoadmin@karmanos.org

Saint Joseph Mercy Brighton
Brighton, Michigan 48114
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Trinity Health IHA Medical Group Hematology Oncology - Brighton
Brighton, Michigan 48114
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

University of Michigan - Brighton Center for Specialty Care
Brighton, Michigan 48116
Contact:
Site Public Contact
800-865-1125

Saint Joseph Mercy Canton
Canton, Michigan 48188
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Trinity Health IHA Medical Group Hematology Oncology - Canton
Canton, Michigan 48188
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Saint Joseph Mercy Chelsea
Chelsea, Michigan 48118
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
Chelsea, Michigan 48118
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

McLaren Cancer Institute-Clarkston
Clarkston, Michigan 48346
Contact:
Site Public Contact
313-576-9790
ctoadmin@karmanos.org

Michigan Healthcare Professionals Clarkston
Clarkston, Michigan 48346
Contact:
Site Public Contact
941-833-5700
rudi.ross@profoundresearch.io

Henry Ford Macomb Hospital-Clinton Township
Clinton Township, Michigan 48038
Contact:
Site Public Contact
313-916-3721
CTOResearch@hfhs.org

Beaumont Hospital - Dearborn
Dearborn, Michigan 48124
Contact:
Site Public Contact
248-551-7695

Wayne State University/Karmanos Cancer Institute
Detroit, Michigan 48201
Contact:
Site Public Contact
313-576-9790
ctoadmin@karmanos.org

Henry Ford Hospital
Detroit, Michigan 48202
Contact:
Site Public Contact
313-916-3721
CTOResearch@hfhs.org

Michigan Healthcare Professionals Farmington
Farmington Hills, Michigan 48334
Contact:
Site Public Contact
941-833-5700
rudi.ross@profoundresearch.io

Weisberg Cancer Treatment Center
Farmington Hills, Michigan 48334
Contact:
Site Public Contact
313-576-9790
ctoadmin@karmanos.org

McLaren Cancer Institute-Flint
Flint, Michigan 48532
Contact:
Site Public Contact
313-576-9790
ctoadmin@karmanos.org

Spectrum Health at Butterworth Campus
Grand Rapids, Michigan 49503
Contact:
Site Public Contact
616-391-1230
crcwm-regulatory@crcwm.org

Trinity Health Grand Rapids Hospital
Grand Rapids, Michigan 49503
Contact:
Site Public Contact
616-391-1230
crcwm-regulatory@crcwm.org

Bronson Methodist Hospital
Kalamazoo, Michigan 49007
Contact:
Site Public Contact
616-391-1230
crcwm-regulatory@crcwm.org

West Michigan Cancer Center
Kalamazoo, Michigan 49007
Contact:
Site Public Contact
616-391-1230
crcwm-regulatory@crcwm.org

Karmanos Cancer Institute at McLaren Greater Lansing
Lansing, Michigan 48910
Contact:
Site Public Contact
313-576-9790
ctoadmin@karmanos.org

Sparrow Hospital
Lansing, Michigan 48912
Contact:
Site Public Contact
517-364-9400

McLaren Cancer Institute-Lapeer Region
Lapeer, Michigan 48446
Contact:
Site Public Contact
313-576-9790
ctoadmin@karmanos.org

Trinity Health Saint Mary Mercy Livonia Hospital
Livonia, Michigan 48154
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Michigan Healthcare Professionals Macomb
Macomb, Michigan 48044
Contact:
Site Public Contact
rudi.ross@profoundresearch.io

Michigan Healthcare Professionals Madison Heights
Madison Heights, Michigan 48071
Contact:
Site Public Contact
941-833-5700
rudi.ross@profoundresearch.io

McLaren Cancer Institute-Macomb
Mount Clemens, Michigan 48043
Contact:
Site Public Contact
313-576-9790
ctoadmin@karmanos.org

McLaren-Port Huron
Port Huron, Michigan 48060
Contact:
Site Public Contact
313-576-9790
ctoadmin@karmanos.org

William Beaumont Hospital-Royal Oak
Royal Oak, Michigan 48073
Contact:
Site Public Contact
248-551-7695

Ascension Saint Mary's Hospital
Saginaw, Michigan 48601
Contact:
Site Public Contact
989-907-8411
lori.srebinski@ascension.org

Marie Yeager Cancer Center
Saint Joseph, Michigan 49085
Contact:
Site Public Contact
616-391-1230
crcwm-regulatory@crcwm.org

Munson Medical Center
Traverse City, Michigan 49684
Contact:
Site Public Contact
616-391-1230
crcwm-regulatory@crcwm.org

William Beaumont Hospital - Troy
Troy, Michigan 48085
Contact:
Site Public Contact
248-551-7695

GenesisCare USA - Troy
Troy, Michigan 48098
Contact:
Site Public Contact
rudi.ross@profoundresearch.io

Henry Ford West Bloomfield Hospital
West Bloomfield, Michigan 48322
Contact:
Site Public Contact
313-916-3721
CTOResearch@hfhs.org

University of Michigan Health - West
Wyoming, Michigan 49519
Contact:
Site Public Contact
616-391-1230
crcwm-regulatory@crcwm.org

Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
Ypsilanti, Michigan 48197
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Mercy Hospital
Coon Rapids, Minnesota 55433
Contact:
Site Public Contact
952-993-1517
mmcorc@healthpartners.com

Miller-Dwan Hospital
Duluth, Minnesota 55805
Contact:
Site Public Contact
218-786-3308
CancerTrials@EssentiaHealth.org

Abbott-Northwestern Hospital
Minneapolis, Minnesota 55407
Contact:
Site Public Contact
952-993-1517
mmcorc@healthpartners.com

Hennepin County Medical Center
Minneapolis, Minnesota 55415
Contact:
Site Public Contact
952-993-1517
mmcorc@healthpartners.com

Monticello Cancer Center
Monticello, Minnesota 55362
Contact:
Site Public Contact
952-993-1517
mmcorc@healthpartners.com

Mayo Clinic in Rochester
Rochester, Minnesota 55905
Contact:
Site Public Contact
855-776-0015

Park Nicollet Clinic - Saint Louis Park
Saint Louis Park, Minnesota 55416
Contact:
Site Public Contact
952-993-1517
mmcorc@healthpartners.com

Regions Hospital
Saint Paul, Minnesota 55101
Contact:
Site Public Contact
952-993-1517
mmcorc@healthpartners.com

University of Mississippi Medical Center
Jackson, Mississippi 39216
Contact:
Site Public Contact
601-815-6700

Saint Francis Medical Center
Cape Girardeau, Missouri 63703
Contact:
Site Public Contact
573-334-2230
sfmc@sfmc.net

MU Health - University Hospital/Ellis Fischel Cancer Center
Columbia, Missouri 65212
Contact:
Site Public Contact
573-882-7440

Siteman Cancer Center at West County Hospital
Creve Coeur, Missouri 63141
Contact:
Site Public Contact
800-600-3606
info@siteman.wustl.edu

Freeman Health System
Joplin, Missouri 64804
Contact:
Site Public Contact
417-347-4030
LJCrockett@freemanhealth.com

University of Kansas Cancer Center - North
Kansas City, Missouri 64154
Contact:
Site Public Contact
913-588-3671
KUCC_Navigation@kumc.edu

University of Kansas Cancer Center - Lee's Summit
Lee's Summit, Missouri 64064
Contact:
Site Public Contact
913-588-3671
KUCC_Navigation@kumc.edu

University of Kansas Cancer Center at North Kansas City Hospital
North Kansas City, Missouri 64116
Contact:
Site Public Contact
913-588-3671
KUCC_Navigation@kumc.edu

Delbert Day Cancer Institute at PCRMC
Rolla, Missouri 65401
Contact:
Site Public Contact
573-458-7504
research@phelpshealth.org

Washington University School of Medicine
Saint Louis, Missouri 63110
Contact:
Site Public Contact
800-600-3606
info@siteman.wustl.edu

Siteman Cancer Center-South County
Saint Louis, Missouri 63129
Contact:
Site Public Contact
800-600-3606
info@siteman.wustl.edu

Missouri Baptist Medical Center
Saint Louis, Missouri 63131
Contact:
Site Public Contact
314-996-5569

Siteman Cancer Center at Christian Hospital
Saint Louis, Missouri 63136
Contact:
Site Public Contact
800-600-3606
info@siteman.wustl.edu

Siteman Cancer Center at Saint Peters Hospital
Saint Peters, Missouri 63376
Contact:
Site Public Contact
800-600-3606
info@siteman.wustl.edu

Mercy Hospital Springfield
Springfield, Missouri 65804
Contact:
Site Public Contact
417-269-4520

Billings Clinic Cancer Center
Billings, Montana 59101
Contact:
Site Public Contact
800-996-2663
research@billingsclinic.org

Benefis Healthcare- Sletten Cancer Institute
Great Falls, Montana 59405
Contact:
Site Public Contact
406-969-6060
mccinfo@mtcancer.org

Nebraska Medicine-Bellevue
Bellevue, Nebraska 68123
Contact:
Site Public Contact
402-559-6941
unmcrsa@unmc.edu

Nebraska Medicine-Village Pointe
Omaha, Nebraska 68118
Contact:
Site Public Contact
402-559-5600

University of Nebraska Medical Center
Omaha, Nebraska 68198
Contact:
Site Public Contact
402-559-6941
unmcrsa@unmc.edu

New Hampshire Oncology Hematology PA-Concord
Concord, New Hampshire 03301
Contact:
Site Public Contact
603-224-2556

Exeter Hospital
Exeter, New Hampshire 03833
Contact:
Site Public Contact
800-439-3837

Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
Lebanon, New Hampshire 03756
Contact:
Site Public Contact
800-639-6918
cancer.research.nurse@dartmouth.edu

Solinsky Center for Cancer Care
Manchester, New Hampshire 03103
Contact:
Site Public Contact
800-339-6484

Cooper Hospital University Medical Center
Camden, New Jersey 08103
Contact:
Site Public Contact
856-325-6757

AtlantiCare Surgery Center
Egg Harbor Township, New Jersey 08234
Contact:
Site Public Contact
609-748-7200

The Cancer Institute of New Jersey Hamilton
Hamilton, New Jersey 08690
Contact:
Site Public Contact
609-631-6946

Saint Barnabas Medical Center
Livingston, New Jersey 07039
Contact:
Site Public Contact
973-322-2934
joanne.loeb@rwjbh.org

Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey 08903
Contact:
Site Public Contact
732-235-7356

Rutgers New Jersey Medical School
Newark, New Jersey 07101
Contact:
Site Public Contact
732-235-7356

The Valley Hospital-Luckow Pavilion
Paramus, New Jersey 07652
Contact:
Site Public Contact
201-634-5792

Valley Hospital
Ridgewood, New Jersey 07450
Contact:
Site Public Contact
201-634-5792
cparish@valleyhealth.com

Robert Wood Johnson University Hospital Somerset
Somerville, New Jersey 08876
Contact:
Site Public Contact
908-685-2481
Siby.Varughese@rwjbh.org

Community Medical Center
Toms River, New Jersey 08755
Contact:
Site Public Contact
732-557-8294
Lennette.Gonzales@rwjbh.org

MD Anderson Cancer Center at Cooper-Voorhees
Voorhees, New Jersey 08043
Contact:
Site Public Contact
856-325-6757

Lovelace Medical Center-Saint Joseph Square
Albuquerque, New Mexico 87102
Contact:
Site Public Contact
505-272-0530
AYost@nmcca.org

University of New Mexico Cancer Center
Albuquerque, New Mexico 87102
Contact:
Site Public Contact
505-925-0348
HSC-ClinicalTrialInfo@salud.unm.edu

Presbyterian Kaseman Hospital
Albuquerque, New Mexico 87110
Contact:
Site Public Contact
505-559-6113
WBurman@phs.org

Presbyterian Rust Medical Center/Jorgensen Cancer Center
Rio Rancho, New Mexico 87124
Contact:
Site Public Contact
505-559-6113
WBurman@phs.org

Northwell Health Imbert Cancer Center
Bay Shore, New York 11706
Contact:
Site Public Contact
516-734-8896

New York-Presbyterian/Brooklyn Methodist Hospital
Brooklyn, New York 11215
Contact:
Site Public Contact
718-780-3677
Adg9003@nyp.org

Roswell Park Cancer Institute
Buffalo, New York 14263
Contact:
Site Public Contact
800-767-9355
askroswell@roswellpark.org

The New York Hospital Medical Center of Queens
Flushing, New York 11355
Contact:
Site Public Contact
412-339-5294
Roster@nrgoncology.org

Northwell Health Physicians Partners Radiation Medicine at Queens
Forest Hills, New York 11375
Contact:
Site Public Contact
718-520-6620

Glens Falls Hospital
Glens Falls, New York 12801
Contact:
Site Public Contact
518-926-6700

Northwell Health/Center for Advanced Medicine
Lake Success, New York 11042
Contact:
Site Public Contact
516-734-8896

Lenox Hill Hospital
New York, New York 10021
Contact:
Site Public Contact
516-734-8896

NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
New York, New York 10032
Contact:
Site Public Contact
212-305-6361
nr2616@cumc.columbia.edu

Manhattan Eye Ear and Throat Hospital
New York, New York 10065
Contact:
Site Public Contact
212-434-4460

NYP/Weill Cornell Medical Center
New York, New York 10065
Contact:
Site Public Contact
212-746-1848

Queens Cancer Center
Rego Park, New York 11374
Contact:
Site Public Contact
718-312-3446

University of Rochester
Rochester, New York 14642
Contact:
Site Public Contact
585-275-5830

Phelps Memorial Hospital Center
Sleepy Hollow, New York 10591
Contact:
Site Public Contact
914-366-1600

Stony Brook University Medical Center
Stony Brook, New York 11794
Contact:
Site Public Contact
800-862-2215

State University of New York Upstate Medical University
Syracuse, New York 13210
Contact:
Site Public Contact
315-464-5476

Westchester Medical Center
Valhalla, New York 10595
Contact:
Site Public Contact
412-339-5294
Roster@nrgoncology.org

Wilmot Cancer Institute at Webster
Webster, New York 14580
Contact:
Site Public Contact
WCICTOresearch@urmc.rochester.edu

Carolinas Medical Center/Levine Cancer Institute
Charlotte, North Carolina 28203
Contact:
Site Public Contact
800-804-9376

Novant Health Presbyterian Medical Center
Charlotte, North Carolina 28204
Contact:
Site Public Contact
980-201-6360
kashah@novanthealth.org

Atrium Health Pineville/LCI-Pineville
Charlotte, North Carolina 28210
Contact:
Site Public Contact
980-442-2000

Atrium Health University City/LCI-University
Charlotte, North Carolina 28262
Contact:
Site Public Contact
800-804-9376

Levine Cancer Institute-Ballantyne
Charlotte, North Carolina 28277
Contact:
Site Public Contact
800-804-9376

Atrium Health Cabarrus/LCI-Concord
Concord, North Carolina 28025
Contact:
Site Public Contact
800-804-9376

Durham VA Medical Center
Durham, North Carolina 27705
Contact:
Site Public Contact
919-286-0411
VHADURcancertrials@va.gov

Duke University Medical Center
Durham, North Carolina 27710
Contact:
Site Public Contact
888-275-3853

Novant Health Cancer Institute - Huntersville
Huntersville, North Carolina 28078
Contact:
Site Public Contact
980-201-6360
kashah@novanthealth.org

Novant Health Cancer Institute - Matthews
Matthews, North Carolina 28105
Contact:
Site Public Contact
980-201-6360
kashah@novanthealth.org

Atrium Health Union/LCI-Union
Monroe, North Carolina 28112
Contact:
Site Public Contact
980-442-2000

Novant Health Cancer Institute - Mooresville
Mooresville, North Carolina 28117
Contact:
Site Public Contact
980-201-6360
kashah@novanthealth.org

UNC Rex Healthcare
Raleigh, North Carolina 27607
Contact:
Site Public Contact
919-784-2500
CancCtrOncologyClinicalResearch@unchealth.unc.edu

Duke Raleigh Hospital
Raleigh, North Carolina 27609
Contact:
Site Public Contact
919-862-5400

UNC Rex Cancer Center of Wakefield
Raleigh, North Carolina 27614
Contact:
Site Public Contact
919-784-2500
CancCtrOncologyClinicalResearch@unchealth.unc.edu

Novant Cancer Institute Radiation Oncology - Supply
Supply, North Carolina 28462
Contact:
Site Public Contact
910-754-4716

Novant Health Cancer Institute Radiation Oncology - Wilmington
Wilmington, North Carolina 28401
Contact:
Site Public Contact
910-251-1839

Novant Health New Hanover Regional Medical Center
Wilmington, North Carolina 28401
Contact:
Site Public Contact
910-342-3000

Novant Health Forsyth Medical Center
Winston-Salem, North Carolina 27103
Contact:
Site Public Contact
336-718-8335
asmarrs@novanthealth.org

Wake Forest University Health Sciences
Winston-Salem, North Carolina 27157
Contact:
Site Public Contact
336-713-6771

Altru Cancer Center
Grand Forks, North Dakota 58201
Contact:
Site Public Contact
701-780-6520

Summa Health System - Akron Campus
Akron, Ohio 44304
Contact:
Site Public Contact
330-375-4221
cancerresearch@summahealth.org

Cleveland Clinic Akron General
Akron, Ohio 44307
Contact:
Site Public Contact
866-223-8100
CancerAnswer@ccf.org

Summa Health System - Barberton Campus
Barberton, Ohio 44203
Contact:
Site Public Contact
330-375-4221
cancerresearch@summahealth.org

Ohio State University Comprehensive Cancer Center
Columbus, Ohio 43210
Contact:
Site Public Contact
800-293-5066
Jamesline@osumc.edu

Summa Health Medina Medical Center
Medina, Ohio 44256
Contact:
Site Public Contact
330-375-4221
cancerresearch@summahealth.org

ProMedica Flower Hospital
Sylvania, Ohio 43560
Contact:
Site Public Contact
419-824-1842
PCIOncResearch@promedica.org

University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma 73104
Contact:
Site Public Contact
405-271-8777
ou-clinical-trials@ouhsc.edu

Legacy Mount Hood Medical Center
Gresham, Oregon 97030
Contact:
Site Public Contact
503-413-2150

Legacy Good Samaritan Hospital and Medical Center
Portland, Oregon 97210
Contact:
Site Public Contact
800-220-4937
cancer@lhs.org

Legacy Meridian Park Hospital
Tualatin, Oregon 97062
Contact:
Site Public Contact
503-413-1742

Saint Luke's Cancer Center - Allentown
Allentown, Pennsylvania 18104
Contact:
Site Public Contact
610-776-4714

UPMC Altoona
Altoona, Pennsylvania 16601
Contact:
Site Public Contact
412-339-5294
Roster@nrgoncology.org

UPMC-Heritage Valley Health System Beaver
Beaver, Pennsylvania 15009
Contact:
Site Public Contact
412-389-5208
haneydl@upmc.edu

Saint Luke's University Hospital-Bethlehem Campus
Bethlehem, Pennsylvania 18015
Contact:
Site Public Contact
484-503-4151

Crozer-Keystone Regional Cancer Center at Broomall
Broomall, Pennsylvania 19008
Contact:
Site Public Contact
610-284-8237
Jolene.garney@crozer.org

Carlisle Regional Cancer Center
Carlisle, Pennsylvania 17015
Contact:
Site Public Contact
412-339-5294
Roster@nrgoncology.org

Christiana Care Health System-Concord Health Center
Chadds Ford, Pennsylvania 19317
Contact:
Site Public Contact
302-623-4450
lbarone@christianacare.org

Chambersburg Hospital
Chambersburg, Pennsylvania 17201
Contact:
Site Public Contact
888-823-5923
ctsucontact@westat.com

Geisinger Medical Center
Danville, Pennsylvania 17822
Contact:
Site Public Contact
570-271-5251
HemonCCTrials@geisinger.edu

Delaware County Memorial Hospital
Drexel Hill, Pennsylvania 19026
Contact:
Site Public Contact
610-284-8237
jolene.garney@crozer.org

Saint Luke's Hospital-Anderson Campus
Easton, Pennsylvania 18045
Contact:
Site Public Contact
412-339-5294
Roster@nrgoncology.org

Ephrata Cancer Center
Ephrata, Pennsylvania 17522
Contact:
Site Public Contact
717-721-4840

UPMC Hillman Cancer Center Erie
Erie, Pennsylvania 16505
Contact:
Site Public Contact
412-389-5208
haneydl@upmc.edu

Saint Vincent Hospital
Erie, Pennsylvania 16544
Contact:
Site Public Contact
814-452-5000

UPMC Cancer Center at UPMC Horizon
Farrell, Pennsylvania 16121
Contact:
Site Public Contact
412-339-5294
Roster@nrgoncology.org

Adams Cancer Center
Gettysburg, Pennsylvania 17325
Contact:
Site Public Contact
877-441-7957

Crozer Regional Cancer Center at Brinton Lake
Glen Mills, Pennsylvania 19342
Contact:
Site Public Contact
610-284-8237

UPMC Cancer Centers - Arnold Palmer Pavilion
Greensburg, Pennsylvania 15601
Contact:
Site Public Contact
724-838-1900

UPMC Pinnacle Cancer Center/Community Osteopathic Campus
Harrisburg, Pennsylvania 17109
Contact:
Site Public Contact
717-724-6765
klitchfield@PINNACLEHEALTH.org

Penn State Milton S Hershey Medical Center
Hershey, Pennsylvania 17033-0850
Contact:
Site Public Contact
717-531-3779
CTO@hmc.psu.edu

IRMC Cancer Center
Indiana, Pennsylvania 15701
Contact:
Site Public Contact
412-389-5208
haneydl@upmc.edu

Jefferson Hospital
Jefferson Hills, Pennsylvania 15025
Contact:
Site Public Contact
412-359-3043
ddefazio@wpahs.org

UPMC-Johnstown/John P. Murtha Regional Cancer Center
Johnstown, Pennsylvania 15901
Contact:
Site Public Contact
814-534-4724

Sechler Family Cancer Center
Lebanon, Pennsylvania 17042
Contact:
Site Public Contact
717-741-8303
doxenberg@wellspan.org

Geisinger Medical Oncology-Lewisburg
Lewisburg, Pennsylvania 17837
Contact:
Site Public Contact
570-374-8555
HemonCCTrials@geisinger.edu

Yolanda G Barco Oncology Institute
Meadville, Pennsylvania 16335
Contact:
Site Public Contact
412-339-5294
Roster@nrgoncology.org

UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion
Mechanicsburg, Pennsylvania 17050
Contact:
Site Public Contact
412-389-5208
haneydl@upmc.edu

Forbes Hospital
Monroeville, Pennsylvania 15146
Contact:
Site Public Contact
412-858-7746

UPMC Cancer Center - Monroeville
Monroeville, Pennsylvania 15146
Contact:
Site Public Contact
412-339-5294
Roster@nrgoncology.org

UPMC Hillman Cancer Center in Coraopolis
Moon, Pennsylvania 15108
Contact:
Site Public Contact
412-389-5208
haneydl@upmc.edu

Thomas Jefferson University Hospital
Philadelphia, Pennsylvania 19107
Contact:
Site Public Contact
215-600-9151
ONCTrialNow@jefferson.edu

Temple University Hospital
Philadelphia, Pennsylvania 19140
Contact:
Site Public Contact
215-728-2983

Allegheny General Hospital
Pittsburgh, Pennsylvania 15212
Contact:
Site Public Contact
877-284-2000

UPMC-Magee Womens Hospital
Pittsburgh, Pennsylvania 15213
Contact:
Site Public Contact
412-647-2811

UPMC-Saint Margaret
Pittsburgh, Pennsylvania 15215
Contact:
Site Public Contact
412-784-4900

West Penn Hospital
Pittsburgh, Pennsylvania 15224
Contact:
Site Public Contact
412-578-5000

University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, Pennsylvania 15232
Contact:
Site Public Contact
412-647-8073

UPMC-Shadyside Hospital
Pittsburgh, Pennsylvania 15232
Contact:
Site Public Contact
412-621-2334

UPMC-Passavant Hospital
Pittsburgh, Pennsylvania 15237
Contact:
Site Public Contact
412-367-6454

UPMC-Saint Clair Hospital Cancer Center
Pittsburgh, Pennsylvania 15243
Contact:
Site Public Contact
412-502-3920

Geisinger Cancer Services-Pottsville
Pottsville, Pennsylvania 17901
Contact:
Site Public Contact
800-275-6401
HemonCCTrials@geisinger.edu

Saint Luke's Hospital - Upper Bucks Campus
Quakertown, Pennsylvania 18951
Contact:
Site Public Contact
610-776-4714

Saint Luke's Hospital-Quakertown Campus
Quakertown, Pennsylvania 18951
Contact:
Site Public Contact
610-776-4714

UPMC Cancer Center at UPMC Northwest
Seneca, Pennsylvania 16346
Contact:
Site Public Contact
814-676-7900

Saint Luke's Hospital - Monroe Campus
Stroudsburg, Pennsylvania 18360
Contact:
Site Public Contact
888-823-5923
ctsucontact@westat.com

UPMC Cancer Center-Uniontown
Uniontown, Pennsylvania 15401
Contact:
Site Public Contact
412-339-5294
Roster@nrgoncology.org

UPMC Uniontown Hospital Radiation Oncology
Uniontown, Pennsylvania 15401
Contact:
Site Public Contact
724-437-2503

UPMC Cancer Center-Washington
Washington, Pennsylvania 15301
Contact:
Site Public Contact
412-339-5294
Roster@nrgoncology.org

UPMC Washington Hospital Radiation Oncology
Washington, Pennsylvania 15301
Contact:
Site Public Contact
724-223-3788
cancer@washingtonhospital.org

Chester County Hospital
West Chester, Pennsylvania 19380
Contact:
Site Public Contact
610-431-5297

Reading Hospital
West Reading, Pennsylvania 19611
Contact:
Site Public Contact
610-988-9323

Wexford Health and Wellness Pavilion
Wexford, Pennsylvania 15090
Contact:
Site Public Contact
Dawnmarie.DeFazio@ahn.org

Geisinger Wyoming Valley/Henry Cancer Center
Wilkes-Barre, Pennsylvania 18711
Contact:
Site Public Contact
570-271-5251
HemonCCTrials@geisinger.edu

Divine Providence Hospital
Williamsport, Pennsylvania 17754
Contact:
Site Public Contact
412-339-5294
Roster@nrgoncology.org

WellSpan Health-York Cancer Center
York, Pennsylvania 17403
Contact:
Site Public Contact
877-441-7957

UPMC Memorial
York, Pennsylvania 17408
Contact:
Site Public Contact
717-724-6760

Rhode Island Hospital
Providence, Rhode Island 02903
Contact:
Site Public Contact
401-444-1488

Smilow Cancer Hospital Care Center - Westerly
Westerly, Rhode Island 02891
Contact:
Site Public Contact
203-785-5702
canceranswers@yale.edu

Saint Joseph's/Candler - Bluffton Campus
Bluffton, South Carolina 29910
Contact:
Site Public Contact
912-819-5704
underberga@sjchs.org

Medical University of South Carolina
Charleston, South Carolina 29425
Contact:
Site Public Contact
843-792-9321
hcc-clinical-trials@musc.edu

Saint Francis Hospital
Greenville, South Carolina 29601
Contact:
Site Public Contact
864-603-6213
melissa_beckman@bshsi.org

Saint Francis Cancer Center
Greenville, South Carolina 29607
Contact:
Site Public Contact
864-603-6213
melissa_beckman@bshsi.org

Self Regional Healthcare
Greenwood, South Carolina 29646
Contact:
Site Public Contact
864-725-4771
nmcgaha@selfregional.org

Gibbs Cancer Center-Pelham
Greer, South Carolina 29651
Contact:
Site Public Contact
864-560-6104
kmertz-rivera@gibbscc.org

Spartanburg Medical Center
Spartanburg, South Carolina 29303
Contact:
Site Public Contact
864-560-6104
kmertz-rivera@gibbscc.org

Houston Methodist San Jacinto Hospital
Baytown, Texas 77521
Contact:
Site Public Contact
412-339-5294
Roster@nrgoncology.org

Houston Methodist Hospital
Houston, Texas 77030
Contact:
Site Public Contact
713-790-2700

Methodist Willowbrook Hospital
Houston, Texas 77070
Contact:
Site Public Contact
412-339-5294
Roster@nrgoncology.org

Houston Methodist Saint John Hospital
Nassau Bay, Texas 77058
Contact:
Site Public Contact
412-339-5294
Roster@nrgoncology.org

University of Texas Health Science Center at San Antonio
San Antonio, Texas 78229
Contact:
Site Public Contact
210-450-3800
phoresearchoffice@uthscsa.edu

Houston Methodist Sugar Land Hospital
Sugar Land, Texas 77479
Contact:
Site Public Contact
281-242-2873

Houston Methodist The Woodlands Hospital
The Woodlands, Texas 77385
Contact:
Site Public Contact
713-790-2700
hmthewoodlands@houstonmethodist.org

American Fork Hospital / Huntsman Intermountain Cancer Center
American Fork, Utah 84003
Contact:
Site Public Contact
801-855-4100
officeofresearch@imail.org

Farmington Health Center
Farmington, Utah 84025
Contact:
Site Public Contact
888-424-2100
cancerinfo@hci.utah.edu

Logan Regional Hospital
Logan, Utah 84321
Contact:
Site Public Contact
435-716-6400
officeofresearch@imail.org

Intermountain Medical Center
Murray, Utah 84107
Contact:
Site Public Contact
801-507-3950
officeofresearch@imail.org

McKay-Dee Hospital Center
Ogden, Utah 84403
Contact:
Site Public Contact
801-387-7426
officeofresearch@imail.org

Utah Valley Regional Medical Center
Provo, Utah 84604
Contact:
Site Public Contact
801-357-7965
officeofresearch@imail.org

Riverton Hospital
Riverton, Utah 84065
Contact:
Site Public Contact
801-507-3950
officeofresearch@imail.org

Saint George Regional Medical Center
Saint George, Utah 84770
Contact:
Site Public Contact
833-321-3332
officeofresearch@imail.org

University of Utah Sugarhouse Health Center
Salt Lake City, Utah 84106
Contact:
Site Public Contact
888-424-2100
cancerinfo@hci.utah.edu

Utah Cancer Specialists-Salt Lake City
Salt Lake City, Utah 84106
Contact:
Site Public Contact
801-933-6070
officeofresearch@imail.org

Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah 84112
Contact:
Site Public Contact
888-424-2100
cancerinfo@hci.utah.edu

LDS Hospital
Salt Lake City, Utah 84143
Contact:
Site Public Contact
801-408-1347
officeofresearch@imail.org

Central Vermont Medical Center/National Life Cancer Treatment
Berlin, Vermont 05602
Contact:
Site Public Contact
802-225-5400

University of Vermont Medical Center
Burlington, Vermont 05401
Contact:
Site Public Contact
802-656-4101
rpo@uvm.edu

Norris Cotton Cancer Center-North
Saint Johnsbury, Vermont 05819
Contact:
Site Public Contact
800-639-6918
cancer.research.nurse@hitchcock.org

Inova Alexandria Hospital
Alexandria, Virginia 22304
Contact:
Site Public Contact
703-776-2580
Stephanie.VanBebber@inova.org

Inova Schar Cancer Institute
Fairfax, Virginia 22031
Contact:
Site Public Contact
703-720-5210
Stephanie.VanBebber@inova.org

Inova Fair Oaks Hospital
Fairfax, Virginia 22033
Contact:
Site Public Contact
703-720-5210
Stephanie.VanBebber@inova.org

Bon Secours Saint Francis Medical Center
Midlothian, Virginia 23114
Contact:
Site Public Contact
804-893-8978
anne_carmellat@bshsi.org

Bon Secours Cancer Institute at Reynolds Crossing
Richmond, Virginia 23230
Contact:
Site Public Contact
804-893-8978
Anne_caramella@bshsi.org

Virginia Commonwealth University/Massey Cancer Center
Richmond, Virginia 23298
Contact:
Site Public Contact
CTOclinops@vcu.edu

Oncology and Hematology Associates of Southwest Virginia
Roanoke, Virginia 24014
Contact:
Site Public Contact
412-339-5294
Roster@nrgoncology.org

Virginia Mason Medical Center
Seattle, Washington 98101
Contact:
Site Public Contact
206-287-6275
cancerresearch@virginiamason.org

Legacy Cancer Institute Medical Oncology and Day Treatment
Vancouver, Washington 98684
Contact:
Site Public Contact
oncologyresearch@lhs.org

Legacy Salmon Creek Hospital
Vancouver, Washington 98686
Contact:
Site Public Contact
503-413-2150

Wheeling Hospital/Schiffler Cancer Center
Wheeling, West Virginia 26003
Contact:
Site Public Contact
304-243-6442

Langlade Hospital and Cancer Center
Antigo, Wisconsin 54409
Contact:
Site Public Contact
715-623-9869
Juli.Alford@aspirus.org

ThedaCare Regional Cancer Center
Appleton, Wisconsin 54911
Contact:
Site Public Contact
920-364-3604
ResearchDept@thedacare.org

Ascension Saint Elizabeth Hospital
Appleton, Wisconsin 54915
Contact:
Site Public Contact
AWRI.inquiry@ascension.org

Northwest Wisconsin Cancer Center
Ashland, Wisconsin 54806
Contact:
Site Public Contact
218-786-3308
CancerTrials@EssentiaHealth.org

Ascension Southeast Wisconsin Hospital - Elmbrook Campus
Brookfield, Wisconsin 53045
Contact:
Site Public Contact
AWRI.Inquiry@Ascension.org

Aurora Cancer Care-Southern Lakes VLCC
Burlington, Wisconsin 53105
Contact:
Site Public Contact
414-302-2304
ncorp@aurora.org

Ascension Calumet Hospital
Chilton, Wisconsin 53014
Contact:
Site Public Contact
AWRI.inquiry@ascension.org

HSHS Sacred Heart Hospital
Eau Claire, Wisconsin 54701
Contact:
Site Public Contact
920-433-8889
ewd_research_admin@hshs.org

Ascension Saint Francis - Reiman Cancer Center
Franklin, Wisconsin 53132
Contact:
Site Public Contact
AWRI.Inquiry@Ascension.org

Aurora Health Care Germantown Health Center
Germantown, Wisconsin 53022
Contact:
Site Public Contact
414-302-2304
ncorp@aurora.org

Aurora Cancer Care-Grafton
Grafton, Wisconsin 53024
Contact:
Site Public Contact
414-302-2304
ncorp@aurora.org

Saint Vincent Hospital Cancer Center Green Bay
Green Bay, Wisconsin 54301
Contact:
Site Public Contact
920-433-8889
ewd_research_admin@hshs.org

Saint Vincent Hospital Cancer Center at Saint Mary's
Green Bay, Wisconsin 54303
Contact:
Site Public Contact
920-433-8889
ewd_research_admin@hshs.org

Aurora BayCare Medical Center
Green Bay, Wisconsin 54311
Contact:
Site Public Contact
414-302-2304
ncorp@aurora.org

Aurora Cancer Care-Kenosha South
Kenosha, Wisconsin 53142
Contact:
Site Public Contact
414-302-2304
ncorp@aurora.org

Mayo Clinic Health System-Franciscan Healthcare
La Crosse, Wisconsin 54601
Contact:
Site Public Contact
855-776-0015

Aurora Bay Area Medical Group-Marinette
Marinette, Wisconsin 54143
Contact:
Site Public Contact
414-302-2304
ncorp@aurora.org

Froedtert Menomonee Falls Hospital
Menomonee Falls, Wisconsin 53051
Contact:
Site Public Contact
262-257-5100

Ascension Columbia Saint Mary's Hospital Ozaukee
Mequon, Wisconsin 53097
Contact:
Site Public Contact
AWRI.Inquiry@Ascension.org

Aurora Cancer Care-Milwaukee
Milwaukee, Wisconsin 53209
Contact:
Site Public Contact
414-302-2304
ncorp@aurora.org

Ascension Columbia Saint Mary's Hospital - Milwaukee
Milwaukee, Wisconsin 53211
Contact:
Site Public Contact
AWRI.Inquiry@Ascension.org

Aurora Saint Luke's Medical Center
Milwaukee, Wisconsin 53215
Contact:
Site Public Contact
414-302-2304
ncorp@aurora.org

Medical College of Wisconsin
Milwaukee, Wisconsin 53226
Contact:
Site Public Contact
414-805-3666

Aurora Sinai Medical Center
Milwaukee, Wisconsin 53233
Contact:
Site Public Contact
414-302-2304
ncorp@aurora.org

Zablocki Veterans Administration Medical Center
Milwaukee, Wisconsin 53295
Contact:
Site Public Contact
888-469-6614

Drexel Town Square Health Center
Oak Creek, Wisconsin 53154
Contact:
Site Public Contact
414-805-0505

Ascension Mercy Hospital
Oshkosh, Wisconsin 54904
Contact:
Site Public Contact
AWRI.inquiry@ascension.org

Vince Lombardi Cancer Clinic - Oshkosh
Oshkosh, Wisconsin 54904
Contact:
Site Public Contact
414-302-2304
ncorp@aurora.org

Ascension All Saints Hospital
Racine, Wisconsin 53405
Contact:
Site Public Contact
AWRI.Inquiry@Ascension.org

Aurora Cancer Care-Racine
Racine, Wisconsin 53406
Contact:
Site Public Contact
414-302-2304
ncorp@aurora.org

Ascension Saint Mary's Hospital
Rhinelander, Wisconsin 54501
Contact:
Site Public Contact
715-847-2353
Beth.Knetter@aspirus.org

Saint Vincent Hospital Cancer Center at Sheboygan
Sheboygan, Wisconsin 53081
Contact:
Site Public Contact
920-433-8889
ewd_research_admin@hshs.org

Vince Lombardi Cancer Clinic-Sheboygan
Sheboygan, Wisconsin 53081
Contact:
Site Public Contact
414-302-2304
ncorp@aurora.org

Ascension Saint Michael's Hospital
Stevens Point, Wisconsin 54481
Contact:
Site Public Contact
715-847-2353
Beth.Knetter@aspirus.org

Saint Vincent Hospital Cancer Center at Sturgeon Bay
Sturgeon Bay, Wisconsin 54235-1495
Contact:
Site Public Contact
920-433-8889
ewd_research_admin@hshs.org

Aurora Medical Center in Summit
Summit, Wisconsin 53066
Contact:
Site Public Contact
414-302-2304
ncorp@aurora.org

Vince Lombardi Cancer Clinic-Two Rivers
Two Rivers, Wisconsin 54241
Contact:
Site Public Contact
414-302-2304
ncorp@aurora.org

Aspirus Regional Cancer Center
Wausau, Wisconsin 54401
Contact:
Site Public Contact
877-405-6866

Ascension Medical Group Southeast Wisconsin - Mayfair Road
Wauwatosa, Wisconsin 53226
Contact:
Site Public Contact
AWRI.Inquiry@Ascension.org

Aurora Cancer Care-Milwaukee West
Wauwatosa, Wisconsin 53226
Contact:
Site Public Contact
414-302-2304
ncorp@aurora.org

Aurora West Allis Medical Center
West Allis, Wisconsin 53227
Contact:
Site Public Contact
414-302-2304
ncorp@aurora.org

Froedtert West Bend Hospital/Kraemer Cancer Center
West Bend, Wisconsin 53095
Contact:
Site Public Contact
414-805-0505

Aspirus Cancer Care - Wisconsin Rapids
Wisconsin Rapids, Wisconsin 54494
Contact:
Site Public Contact
715-422-7718

More Details

NCT ID
NCT04513717
Status
Recruiting
Sponsor
NRG Oncology

Detailed Description

PRIMARY OBJECTIVES: I. To determine whether men with National Comprehensive Cancer Network (NCCN) high risk prostate cancer who are in the lower 2/3 of Decipher genomic risk (=< 0.85) can be treated with 12 months androgen deprivation therapy (ADT) plus radiation therapy (RT) instead of 24 months ADT+RT and experience non-inferior metastasis-free survival. (De-intensification study) II. To determine whether men with NCCN high risk prostate cancer who are in the upper 1/3 of Decipher genomic risk (> 0.85) or have node-positive disease by conventional imaging (magnetic resonance imaging [MRI] or computed tomography [CT] scan) will have a superior metastasis-free survival (MFS) through treatment intensification with apalutamide added to the standard of RT plus 24 month ADT. (Intensification study) SECONDARY OBJECTIVES: I. To compare overall survival (OS) between the standard of care (RT plus 24 months of ADT) and either the de-intensification (RT plus 12 months of ADT) or intensification arm (RT plus 24 months of ADT plus apalutamide). (De-intensification and intensification studies) II. To compare time to prostate specific antigen (PSA) failure or start of salvage treatment between the standard of care (RT plus 24 months of ADT) and either the de-intensification arm (RT plus 12 months of ADT) or intensification arm (RT plus 24 months of ADT plus apalutamide). (De-intensification and intensification studies) III. To compare PSA failure-free survival with non-castrate testosterone and no additional therapies between the standard of care (RT plus 24 months of ADT) and either the de-intensification arm (RT plus 12 months of ADT) or intensification arm (RT plus 24 months of ADT plus apalutamide). (De-intensification and intensification studies) IV. To compare MFS judged based on either standard or molecular imaging between the standard of care (RT plus 24 months of ADT) and either the de-intensification arm (RT plus 12 months of ADT) or intensification arm (RT plus 24 months of ADT plus apalutamide). (De-intensification and intensification studies) V. To compare prostate cancer-specific mortality between the standard of care (RT plus 24 months of ADT) and either the de-intensification arm (RT plus 12 months of ADT) or intensification arm (RT plus 24 months of ADT plus apalutamide). (De-intensification and intensification studies) VI. To compare testosterone levels at the time of PSA failure and metastases between the standard of care (RT plus 24 months of ADT) and either the de-intensification arm (RT plus 12 months of ADT) or intensification arm (RT plus 24 months of ADT plus apalutamide). (De-intensification and intensification studies) VII. To compare time to testosterone recovery (defined as a T > 200) between the standard of care (RT plus 24 months of ADT) and either the de-intensification arm (RT plus 12 months of ADT) or intensification arm (RT plus 24 months of ADT plus apalutamide). (De-intensification and intensification studies) VIII. To compare adverse events, both clinician-reported using Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0 and patient-reported using Patient Reported Outcome (PRO)-CTCAE items, between the standard of care (RT plus 24 months of ADT) and either the de-intensification arm (RT plus 12 months of ADT) or intensification arm (RT plus 24 months of ADT plus apalutamide). (De-intensification and intensification studies) EXPLORATORY OBJECTIVES: I. To compare changes in cardio-metabolic markers, including body mass index, and waist circumference, between the standard of care (RT plus 24 months of ADT) and either the de-intensification arm (RT plus 12 months of ADT) or intensification arm (RT plus 24 months of ADT plus apalutamide). (De-intensification and intensification studies) II. To determine a machine learning/artificial intelligence algorithm for radiotherapy quality assurance. (De-intensification and Intensification studies) III. To perform future translational correlative studies using biological and imaging data. (De-intensification and intensification studies) IV. Impact of PET use in high-risk prostate cancer PATIENT-REPORTED OUTCOMES OBJECTIVES: PRIMARY OBJECTIVES: I. To compare sexual and hormonal function related quality of life, as measured by the Expanded Prostate Cancer Index Composite-26 (EPIC), between the standard of care (RT plus 24 months of ADT) and the de-intensification arm (RT plus 12 months of ADT). (De-Intensification Study) II. To compare fatigue, as measured by the Patient Reported Outcomes Measurement Information System (PROMIS)-Fatigue instrument, between the standard of care (RT plus 24 months of ADT) and the intensification arm (RT plus 24 months of ADT plus apalutamide). (Intensification Study) SECONDARY OBJECTIVES: I. To compare depression, as measured by the PROMIS-depression, between the standard of care (RT plus 24 months of ADT) and the de-intensification arm (RT plus 12 months of ADT). (De-Intensification Study) II. To compare depression, as measured by the PROMIS-depression, between the standard of care (RT plus 24 months of ADT) and the intensification arm (RT plus 24 months of ADT plus apalutamide). (Intensification Study) EXPLORATORY OBJECTIVES: I. To compare cognition, as measured by the Functional Assessment of Chronic Illness Therapy-Cognitive (FACT-Cog) perceived cognitive abilities subscale, between the standard of care (RT plus 24 months of ADT) and the de-intensification arm (RT plus 12 months of ADT). (De-Intensification Study) II. To compare bowel and urinary function related quality of life, as measured by the Expanded Prostate Cancer Index Composite-26 (EPIC), between the standard of care (RT plus 24 months of ADT) and the de-intensification arm (RT plus 12 months of ADT). (De-Intensification Study) III. To compare fatigue, as measured by the PROMIS-Fatigue instrument, between the standard of care (RT plus 24 months of ADT) and the de-intensification arm (RT plus 12 months of ADT). (De-Intensification Study) IV. To compare sexual and hormonal function related quality of life, as measured by the Expanded Prostate Cancer Index Composite-26 (EPIC), between the standard of care (RT plus 24 months of ADT) and the intensification arm (RT plus 24 months of ADT plus apalutamide). (Intensification Study) V. To compare bowel and urinary function related quality of life, as measured by the Expanded Prostate Cancer Index Composite-26 (EPIC), between the standard of care (RT plus 24 months of ADT) and the intensification arm (RT plus 24 months of ADT plus apalutamide). (Intensification Study) VI. To compare cognition, as measured by the Functional Assessment of Chronic Illness Therapy-Cognitive (FACT-Cog) perceived cognitive abilities subscale, between the standard of care (RT plus 24 months of ADT) and the intensification arm (RT plus 24 months of ADT plus apalutamide). (Intensification Study) OUTLINE: Patients are randomized to 1 of 4 arms. DE-INTENSIFICATION STUDY (DECIPHER SCORE =< 0.85): ARM I: Patients undergo radiation therapy (RT) over 2-11 weeks and receive ADT (consisting of either leuprolide, goserelin, triptorelin, degarelix, buserelin or histrelin and bicalutamide or flutamide) for 24 months in the absence of disease progression or unacceptable toxicity. ARM II: Patients undergo RT over 2-11 weeks and receive ADT (consisting of either leuprolide, goserelin, triptorelin, degarelix, buserelin or histrelin and bicalutamide or flutamide) for 12 months in the absence of disease progression or unacceptable toxicity. INTENSIFICATION STUDY (DECIPHER SCORE > 0.85 OR NODE POSITIVE): ARM III: Patients undergo RT over 2-11 weeks and receive ADT (consisting of either leuprolide, goserelin, triptorelin, degarelix, buserelin or histrelin and bicalutamide or flutamide) for 24 months in the absence of disease progression or unacceptable toxicity. ARM IV: Patients undergo RT over 2-11 weeks and receive ADT (consisting of either leuprolide, goserelin, triptorelin, degarelix, buserelin or histrelin) for 24 months in the absence of disease progression or unacceptable toxicity. Patients also receive apalutamide orally (PO) once daily (QD). Treatment repeats every 90 days for up to 8 cycles (24 months) in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up annually.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.